Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

10.00
+0.48005.04%
Post-market: 10.000.0006+0.01%19:56 EST
Volume:15.19M
Turnover:152.73M
Market Cap:1.40B
PE:-2.99
High:10.40
Open:9.34
Low:9.30
Close:9.52
52wk High:18.48
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.77
T/O Rate:11.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-62.60%
ROA:-29.87%
PB:2.28
PE(LYR):-2.62

Loading ...

Intellia Shares Gain Attention After FDA Priority Review And Trial Progress

Simply Wall St.
·
11 hours ago

Intellia Therapeutics, Inc.: Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Yesterday

Intellia Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Yesterday

Movement Alert|Intellia Therapeutics Intraday Rise 5.24% in Regular Trading, Phase 3 enrollment completion and reiterated Buy rating support sentiment

Market Focus
·
Nov 20

Movement Alert|Intellia Therapeutics Falls 5.22% in Regular Trading, focus returns to earnings pressure after recent clinical milestone

Market Focus
·
Nov 20

Movement Alert|Intellia Therapeutics Intraday Rise 5.32% in Regular Trading, Phase 3 Enrollment Completion and Buy Rating Support Sentiment

Market Focus
·
Nov 18

Intellia Therapeutics (NTLA) Faces A Fresh Valuation Test After Phase 3 Enrollment Wraps

Simply Wall St.
·
Nov 18

Intellia Therapeutics (NTLA) Receives a Buy from Canaccord Genuity

TIPRANKS
·
Nov 16

Intellia Therapeutics Stock In Focus As HAE Gene Editing Wins Priority Review

Simply Wall St.
·
Nov 14

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Nov 14

Intellia's Lonvo-Z Cuts HAE Attack Rate 81% Versus Prior Prophylaxis in Phase 3 Trial

Reuters
·
Nov 12

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

GlobeNewswire
·
Nov 12

Intellia Therapeutics (NTLA) Completes Phase 3 Enrollment As Investors Ask If It Is Still A Bargain

Simply Wall St.
·
Nov 11

Intellia Therapeutics price target raised to $9 from $8 at JPMorgan

TIPRANKS
·
Nov 09

Should Phase 3 Enrollment Completion Require Action From Intellia Therapeutics (NTLA) Investors?

Simply Wall St.
·
Nov 07

JonesTrading Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
Nov 07

Intellia Therapeutics Grants 12,900 Restricted Stock Units to Three New Employees

Reuters
·
Nov 07

Intellia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Nov 07

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 07

Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
Nov 06